Strategic Plan Objective Detail
Interagency Autism Coordinating Committee (IACC) logo
Office of Autism Research Coordination (OARC) logo

Question 4: Short-term Objective B  

$20,162,709.18
Fiscal Year: 2009

Green dot: Objective has greater than or equal to the recommended funding.4SB. Standardize and validate at least 20 model systems (e.g., cellular and/or animal) that replicate features of ASD and will allow identification of specific molecular targets or neural circuits amenable to existing or new interventions by 2012. IACC Recommended Budget: $75,000,000 over 5 years.

Download 2009 Question 4: Short-term Objective B projects (EXCEL)
Note: Initial Sort is by Principal Investigator. Sorting by other columns is available by clicking on the desired column header.
Project Title Principal Investigator Institution
Function and dysfunction of neuroligins Sudhof, Thomas Stanford University
Genomic imbalances at the 22q11 locus and predisposition to autism Gogos, Joseph Columbia University
Genomic resources for identifying genes regulating social behavior Young, Larry Emory University
Integrated approach to the neurobiology of autism spectrum disorders Vaccarino, Flora Yale University
Investigation of the role of MET kinase in autism Dawson, Ted Johns Hopkins University School of Medicine
Mice lacking Shank postsynaptic scaffolds as an animal model of autism Sheng, Morgan Massachusetts Institute of Technology
Modeling and pharmacologic treatment of autism spectrum disorders in Drosophila McDonald, Thomas Albert Einstein College of Medicine of Yeshiva University
Molecular determinants of L-type calcium channel gating Colecraft, Henry Columbia University
Mouse genetic model of a dysregulated serotonin transporter variant associated with autism Veenstra-Vanderweele, Jeremy Vanderbilt University
Neural and cognitive mechanisms of autism Sur, Mriganka Massachusetts Institute of Technology
Neural mechanisms of social cognition and bonding Young, Larry Emory University
Neurexin-neuroligin trans-synaptic interaction in learning and memory Kandel, Eric Columbia University
Neurobiological mechanism of 15q11-13 duplication autism spectrum disorder Anderson, Matthew Beth Israel Deaconess Medical Center
Neurobiology of sociability in a mouse model system relevant to autism Brodkin, Edward University of Pennsylvania
Neurobiology of sociability in a mouse model system relevant to autism (supplement) Brodkin, Edward University of Pennsylvania
Neurogenetic model of social behavior heterogeneity in autism spectrum disorders Platt, Michael Duke University
Neurogenomics in a model for procedural learning Hilliard, Austin University of California, Los Angeles
Neuropharmacology of motivation and reinforcement in mouse models of autistic spectrum disorders Malanga, C.J. University of North Carolina School of Medicine
Novel genetic animal models of autism Powell, Craig University of Texas Southwestern Medical Center
Novel models to define the genetic basis of autism Mills, Alea Cold Spring Harbor Laboratory
Perturbed activity-dependent plasticity mechanisms in autism Sabatini, Bernardo Harvard Medical School
Primate models of autism Amaral, David University of California, Davis
Probing disrupted cortico-thalamic interactions in autism spectrum disorders Fagiolini, Michela Children's Hospital Boston
Regulation of synaptogenesis by cyclin-dependent kinase 5 Tsai, Li-Huei Massachusetts Institute of Technology
Role of a novel Wnt pathway in autism spectrum disorders Reichardt, Louis University of California, San Francisco

Objective Cumulative Funding Table

IACC Strategic Plan Objective 2008 2009 2010 2011 2012 Total
Standardize and validate at least 20 model systems (e.g., cellular and/or animal) that replicate features of ASD and will allow identification of specific molecular targets or neural circuits amenable to existing or new interventions by 2012.

IACC Recommended Budget: $75,000,000 over 5 years
4.5
$15,879,827
42 projects

4.S.B
$20,162,709
70 projects

4.S.B
$23,229,501
92 projects

4.S.B
$21,606,118
89 projects

4.S.B
$21,232,514
94 projects

$102,110,669
4.S.B. Funding: The recommended budget was met. Significantly more than the recommended minimum budget was allocated to projects specific to this objective.

Progress: More than 90 projects were supported to develop animal models.

Remaining Gaps, Needs, and Opportunities: Planning Group members discussed whether the amount of investment in this area is appropriate when compared to investments in clinical trials and other later stage studies. Invited experts suggested that the current stage of scientific research in ASD requires pre-clinical research to identify targets from animal and cellular models. Similar to cancer treatment development pathways, which spanned 20-30 years, research in ASD must invest in model systems to understand the fundamental biology from which translation to the clinic can be built. The translational validity of research in non-human animals cannot be determined until human trials are conducted, thus the need for rapid progress to clinical studies in humans is important.